Abstract
Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have